Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
Key regions: Brazil, India, Australia, United States, United Kingdom
The Antiviral Drugs market in Benelux has been experiencing steady growth in recent years.
Customer preferences: Customers in the Benelux region have shown a growing demand for antiviral drugs due to the increasing prevalence of viral infections. This includes both prescription and over-the-counter drugs, with a preference for those that are effective against a wide range of viruses.
Trends in the market: One of the major trends in the Antiviral Drugs market in Benelux is the increasing focus on research and development of new drugs. This is driven by the need for more effective treatments for viral infections, as well as the potential for significant profits for pharmaceutical companies that are able to develop successful drugs. Another trend is the growing popularity of natural antiviral remedies, which are seen as a safer and more sustainable alternative to traditional drugs.
Local special circumstances: The Benelux region has a highly developed healthcare system, which has contributed to the growth of the Antiviral Drugs market. The region also has a large aging population, who are particularly vulnerable to viral infections and therefore have a high demand for antiviral drugs. Additionally, the region has a strong pharmaceutical industry, which has helped to drive innovation and research in the Antiviral Drugs market.
Underlying macroeconomic factors: The growth of the Antiviral Drugs market in Benelux is also influenced by broader macroeconomic factors. For example, rising healthcare costs and increasing government investment in healthcare have contributed to the growth of the market. Additionally, the region's strong economy and high standards of living have made it an attractive market for pharmaceutical companies looking to expand their operations.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)